外用抗真菌药物治疗甲真菌病进展

摘要/Abstract

摘要：

本文就外用抗真菌药物治疗甲真菌病进展进行综述，包括在临床上已广泛应用的8%环吡酮甲涂剂及5%阿莫罗芬搽剂，美国FDA批准的两个新药10%艾氟康唑溶液及5%Tavaborole溶液，以及一些尚在研究中的卢立康唑、他扎罗汀等，并简述外用抗真菌药物治疗甲真菌病新剂型的应用。

关键词: 甲真菌病, 10%艾氟康唑溶液, 5%Tavaborole溶液, 外用

Abstract:

In this article, we reviewed topical antifungal agents for the treatment of onychomycosis at present, including the widely used agents, 8% ciclopirox nail lacquer and 5% amorolfine nail lacquer, and the agents recently approved by the FDA, 10% efinaconazole and 5% tavaborole solution, as well as luliconazole and tazarotene which being still in studies. The use of new formulations of topical antifungal drugs were also included in this review.

Key words: onychomycosis, efinaconazole, tavaborole, topical

中图分类号:

R756.4

王若珺, 李若瑜, 王爱平. 外用抗真菌药物治疗甲真菌病进展[J]. 中国真菌学杂志, 2018, 13(2): 114-119.

WANG Ruo-jun, LI Ruo-yu, WANG Ai-ping. Progess of topical antifungal agents for the treatment of onychomycosis[J]. Chinese Journal of Mycology, 2018, 13(2): 114-119.

参考文献

[1] James Q, Del Rosso. The Role of Topical Antifungal Therapy for Onychomycosis and the Emergence of Newer Agents[J]. J Clin Aesthet Dermatol,2014,7(7):10-18.
[2] Gupta AK, Versteeg SG. Tavaborole-a treatment for onychomycosis of the toenails[J]. Expert Rev Clin Pharmacol,2016,9(9):1145-1152.
[3] 李若瑜. 甲真菌病的诊断和治疗进展. 实用皮肤病学杂志[J],2013,6(2):93-95.
[4] Tabara K, Szewczyk AE, Bienias W, et al. Amorolfine vs. ciclopirox-lacquers for the treatment of onychomycosis[J]. Postepy Dermatol Alergol,2015,32(1):40-45.
[5] Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis[J]. J Am Acad Dermatol,2000,43(Suppl4):S57-69.
[6] Zane LT, Chanda S, Coronado D, et al. Antifungal agents for onychomycosis:new treatment strategies to improve safety[J]. Dermatol Online J,2016,16:22(3):1-13.
[7] Avner S, Nir N, Henri T. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis[J]. J Dermatolog Treat,2005,16(5-6):327-330.
[8] Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis[J]. J Am Acad Dermatol,2000,43(4 Suppl):S70-S80.
[9] Shemer A, Nathansohn N, Trau H, et al. Ciclopirox nail lacquer for the treatment of onychomycosis:an open non-comparative study[J]. J Dermatol,2010,37(2):137-139.
[10] Gupta AK, Onychomycosis Combination Therapy Study Group. Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis:a randomized, evaluator-blinded study[J]. J Drugs Dermatol,2005,4(4):481-485.
[11] Monti D, Herranz U, Dal Bo L, et al. Nail penetration and predicted mycological efficacy of an innovative hydrosoluble ciclopirox nail lacquer vs. a standard amorolfine lacquer in healthy subjects[J]. J Eur Acad Dermatol Venereol, 2013,27(2):e153-158.
[12] 王爱平, 李若瑜. 5%盐酸阿莫罗芬搽剂在甲真菌病中的应用[J]. 中国真菌学杂志, 2015,10(5):317-320.
[13] Sigurgeirsson B, Olafsson JH, Steinsson JT, et al. Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years[J]. J Eur Acad Dermatol Venereol,2010,24(8):910-915.
[14] Bunyaratavej S, Leeyaphan C, Rujitharanawong C, et al. Efficacy of 5% amorolfine nail lacquer in Neoscytalidium dimidiatum onychomycosis[J]. J Dermatolog Treat,2016,27(4):359-363.
[15] Chen S, Ran YP, Dai YL, et al. Case of infantile onychomycosis successfully cured by 5% amorolfine nail lacquer[J]. J Paediatr Child Health,2014,50(11):933-934.
[16] Baran R, Sigurgeirsson B, de Berker D, et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement[J]. Br J Dermatol,2007,157(1):149-157.
[17] Rigopoulos D, Katoulis AC, Ioannides D, et al. A randomized trial of amorolfine 5% solution nail lacquer in association with itraconazole pulse therapy compared with itraconazole alone in the treatment of Candida fingernail onychomycosis[J]. Br J Dermatol,2003,149(1):151-156.
[18] Feng X, Xiong X, Ran Y. Efficacy and tolerability of amorolfine 5% nail lacquer in combination with systemic antifungal agents for onychomycosis:A meta-analysis and systematic review[J]. Dermatol Ther,2017,30(3):1-6.
[19] Tatsumi Y, Nagashima M, Shibanushi T, et al. Mechanism of action of efinaconazole, a novel triazole antifungal agent[J]. Antimicrob Agents Chemother, 2013,57(5):2405-2409.
[20] Jo Siu WJ, Tatsumi Y, Senda H, et al. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis[J]. Antimicrob Agents Chemother, 2013,57(4):1610-1616.
[21] Pollak RA. Efinaconazole topical solution, 10%:the development of a new topical treatment for toenail onychomycosis[J]. J Am Podiatr Med Assoc,2014,104(6):568-573.
[22] Shari R Lipner, Richard K Scher. Efinaconazole in the treatment of onychomycosis[J]. Infect Drug Resist, 2015, 8:163-172.
[23] Rock FL, Mao W, Yaremchuk A, et al. An antifungal agent inhibits an aminoacyl-RNA synthetase by trapping tRNA in the editing site[J]. Science,2007,316(5832):1759-1761.
[24] Coronado D, Merchant T, Chanda S, et al. In vitro nail penetration and antifungal activity of tavaborole, a boron-based pharmaceutical[J]. J Drugs Dermatol, 2015,14(6):609-614.
[25] Saunders J, Maki K, Koski R, et al. Tavaborole, efinaconazole, and luliconazole:three new antimycotic agents for the treatment of dermatophytic fungi[J]. J Pharm Pract,2016:1-10.
[26] Gupta AK, Daigle D. Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults[J]. Expert Rev Anti Infect Ther,2014,12(7):735-742.
[27] Gupta AK, Hall S, Zane LT, et al. Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults:a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies[J]. J Dermatolog Treat,2017:1-5.
[28] Ciaravino V, Coronado D, Lanphear C, et al. Tavaborole, a novel boron-containing small molecule pharmaceutical agent for topical treatment of onychomycosis:I. reproductive and developmental toxicity studies[J]. Int J Toxicol,2016,35(5):530-542.
[29] Flores FC, Rosso RS, Cruz L, et al. An innovative polysaccharide nanobased nail formulation for improvement of onychomycosis treatment[J]. Eur J Pharm Sci,2017,100:56-63.
[30] Ribeiro RF, Motta MH, H rter APG, et al. Spray-dried powders improve the controlled release of antifungal tioconazole-loaded polymeric nanocapsules compared to with lyophilized products[J]. Mater Sci Eng C Mater Biol Appl,2016,59:875-884.
[31] Watanabe S, Kishida H, Okubo A. Efficacy and safety of luliconazole 5% nail solution for the treatment of onychomycosis:a multicenter, double-blind, randomized phase Ⅲ study[J]. J Dermatol,2017,44(7):753-759.
[32] Wiederhold NP, Fothergill AW, McCarthy DI, et al. Luliconazole demonstrates potent in vitro activity against dermatophytes recovered from patients with onychomycosis[J]. Antimicrob Agents Chemother,2014,58(6):3553-3555.
[33] Campione E, Paternò EJ, Costanza G, et al. Tazarotene as alternative topical treatment for onychomycosis[J]. Drug Des Devel Ther, 2015,9:879-886.
[34] Auvinen T, Tiihonen R, Soini M, et al. Efficacy of topical resin lacquer, amorolfine and oral terbinafine for treating toenail onychomycosis:a prospective, randomized, controlled, investigator-blinded, parallel-group clinical trial[J]. Br J Dermatol,2015,173(4):940-948.
[35] Yuji Tabata, Naomi Takei-Masuda, Natsuki Kubota, et al. Characterization of antifungal activity and nail penetration of ME1111, a new antifungal agent for topical treatment of onychomycosis[J]. Antimicrob Agents Chemother,2016,60(2):1035-1039.
[36] Zhou BR, Lu Y, Permatasari F, et al. The efficacy of fractional carbon dioxide (CO₂) laser combined with luliconazole 1% cream for the treatment of onychomycosis:A randomized, controlled trial[J]. Medicine (Baltimore),2016,95(44):e5141.
[37] Bhatta AK, Keyal U, Huang X, et al. Fractional carbon-dioxide (CO₂) laser-assisted topical therapy for the treatment of onychomycosis[J]. J Am Acad Dermatol, 2016,74(5):916-923.